Bill Detail

H.R. 1843

Congress: 119

Title

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Summary

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Sponsor

Rep. Neal Dunn [R-FL-2]

Status

Referred to the House Committee on Energy and Commerce.

Status as of Nov 13, 2026, 7:16 AM · synced 3d ago

Introduced

2025-03-05

Data source mode: congress-gov

Bill Engagement

Lobbyists on the case

2 orgs · 38 lobbyists · 2 filings mention H.R. 1843 (To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.) in LDA disclosures.

These are cached disclosure mentions, not verified current representation or confirmed event attendance.

Top orgs filing
Lobbyists on this bill
+ 36 more in the full intelligence view

Limited preview · paid intelligence

Keep the intelligence current—not just this one record.

Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.

Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.

Buy Federal Intelligence · $2,500 for 3 monthsRequest a Sample by EmailPrefer a walkthrough first?Already a customer? Sign inGet free intelligence alerts →

After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.